Subtopic Deep Dive
Bariatric Surgery Remission of Type 2 Diabetes
Research Guide
What is Bariatric Surgery Remission of Type 2 Diabetes?
Bariatric surgery remission of type 2 diabetes refers to the sustained normalization of blood glucose levels in obese patients with T2D following procedures like RYGB or sleeve gastrectomy, often surpassing intensive medical therapy alone.
Long-term RCTs demonstrate remission rates exceeding 50% at 5 years post-surgery compared to <10% with medical management (Schauer et al., 2017; 2724 citations). Key mechanisms involve gut hormone alterations and beta-cell function recovery. Over 20 RCTs and meta-analyses, including SOS trial follow-ups, confirm superior glycemic control (Sjöström et al., 2004; 4410 citations).
Why It Matters
Bariatric surgery achieves T2D remission in 60-80% of patients at 1-3 years, dropping to 30-50% at 5 years, far outperforming medical therapy's 5-20% rates and influencing ADA guidelines for BMI>35 with poor control (Schauer et al., 2012; Schauer et al., 2017). SOS trial showed 72% diabetes incidence reduction versus conventional therapy over 10-20 years, reducing cardiovascular events (Sjöström et al., 2004; Sjöström, 2013). Meta-analyses confirm 1.5-2x higher odds of remission, shifting treatment paradigms for 400M+ global T2D cases (Gloy et al., 2013).
Key Research Challenges
Durability of Remission
Remission rates decline from 72% at 2 years to 30-38% at 5 years post-RYGB, questioning long-term efficacy (Schauer et al., 2017). Mechanisms like beta-cell recovery may not persist without sustained weight loss (Schauer et al., 2014). RCTs show higher relapse in lower BMI patients.
Mechanisms Identification
Gut hormone changes (GLP-1, PYY) drive early remission, but beta-cell function recovery timelines remain unclear (Schauer et al., 2012). Distinguishing weight loss-independent effects requires longitudinal biomarkers beyond HbA1c (Sjöström, 2013).
Patient Selection Optimization
Remission predictors like diabetes duration <5 years and BMI 30-40 vary by procedure; sleeve gastrectomy shows 50% rates vs RYGB's 70% (Gloy et al., 2013). RCTs exclude extremes, limiting generalizability to super-obese or elderly T2D patients (Schauer et al., 2017).
Essential Papers
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
Lars Sjöström, Anna‐Karin Lindroos, Markku Peltonen et al. · 2004 · New England Journal of Medicine · 4.4K citations
As compared with conventional therapy, bariatric surgery appears to be a viable option for the treatment of severe obesity, resulting in long-term weight loss, improved lifestyle, and, except for h...
European Guidelines for Obesity Management in Adults
Volkan Yumuk, Constantine Tsigos, Martin Fried et al. · 2015 · Obesity Facts · 3.3K citations
Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting...
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Rena R. Wing · 2013 · New England Journal of Medicine · 2.8K citations
An intensive lifestyle intervention focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults with type 2 diabetes. (Funded by the National Institutes o...
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Philip R. Schauer, Deepak L. Bhatt, John P. Kirwan et al. · 2017 · New England Journal of Medicine · 2.7K citations
Five-year outcome data showed that, among patients with type 2 diabetes and a BMI of 27 to 43, bariatric surgery plus intensive medical therapy was more effective than intensive medical therapy alo...
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Philip R. Schauer, Sangeeta R. Kashyap, Kathy Wolski et al. · 2012 · New England Journal of Medicine · 2.1K citations
In obese patients with uncontrolled type 2 diabetes, 12 months of medical therapy plus bariatric surgery achieved glycemic control in significantly more patients than medical therapy alone. Further...
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
Philip R. Schauer, Deepak L. Bhatt, John P. Kirwan et al. · 2014 · New England Journal of Medicine · 1.9K citations
Among obese patients with uncontrolled type 2 diabetes, 3 years of intensive medical therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did medical ther...
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing, Wei Lang, Thomas A. Wadden et al. · 2011 · Diabetes Care · 1.8K citations
OBJECTIVE Overweight and obese individuals are encouraged to lose 5–10% of their body weight to improve cardiovascular disease (CVD) risk, but data supporting this recommendation are limited, parti...
Reading Guide
Foundational Papers
Start with Sjöström et al. (2004; 4410 citations) for SOS 10-year outcomes establishing surgery's diabetes benefits; follow with Schauer et al. (2012; 2131 citations) 1-year RCT and 2014 3-year update (1872 citations) for direct medical therapy comparisons.
Recent Advances
Schauer et al. (2017; 2724 citations) provides 5-year RCT data confirming superior remission; Gloy et al. (2013; 1313 citations) meta-analysis synthesizes RCT evidence.
Core Methods
RCTs use intention-to-treat analysis of HbA1c remission (HbA1c<6.5% off meds); mixed-effects models for longitudinal data; meta-analyses employ random-effects ORs for remission rates (Schauer series; Gloy et al., 2013).
How PapersFlow Helps You Research Bariatric Surgery Remission of Type 2 Diabetes
Discover & Search
Research Agent uses searchPapers('bariatric surgery T2D remission RCT') to retrieve Schauer et al. (2017) NEJM paper (2724 citations), then citationGraph reveals SOS cluster (Sjöström 2004) and meta-analyses; exaSearch uncovers 50+ related trials; findSimilarPapers expands to Gloy et al. (2013) BMJ meta-analysis.
Analyze & Verify
Analysis Agent applies readPaperContent on Schauer et al. (2017) to extract 5-year remission rates (38% RYGB vs 5% medical), verifies via CoVe against Sjöström (2004) 10-year data, and runPythonAnalysis computes meta-analytic odds ratios from Look AHEAD/Look AHEAD-like datasets using GRADE for high-quality RCT evidence.
Synthesize & Write
Synthesis Agent detects gaps in long-term (>10y) relapse mechanisms between Schauer series and SOS, flags contradictions in BMI thresholds; Writing Agent uses latexEditText for remission rate tables, latexSyncCitations for 20-paper bibliography, latexCompile for review manuscript, exportMermaid for RCT flowchart comparisons.
Use Cases
"Compare 5-year T2D remission rates across RYGB, sleeve, and medical therapy in RCTs"
Research Agent → searchPapers + citationGraph (Schauer 2017/Sjöström 2004) → Analysis Agent → runPythonAnalysis (pandas meta-analysis of HbA1c remission) → Synthesis Agent → exportMermaid (remission rate timeline diagram).
"Write LaTeX review section on bariatric surgery vs medical therapy for T2D"
Research Agent → findSimilarPapers (Schauer series) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (20 papers) + latexCompile → formatted PDF with tables/figures.
"Extract statistical models from T2D remission RCTs for replication"
Research Agent → exaSearch('RYGB diabetes remission models') → Analysis Agent → readPaperContent → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (survival analysis R scripts from Schauer datasets).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(250M corpus) → citationGraph(Schauer/Sjöström clusters) → DeepScan 7-steps analyzes 50+ RCTs with GRADE scoring and CoVe verification → structured report on remission ORs. Theorizer generates hypotheses on gut hormone-beta cell interactions from SOS/Schauer abstracts. DeepScan checkpoint verifies 10-year durability claims against Sjöström (2004).
Frequently Asked Questions
What defines T2D remission post-bariatric surgery?
Remission is HbA1c <6.5% without glucose-lowering drugs for ≥1 year; Schauer et al. (2012) reported 66% at 1 year vs 11% medical therapy.
What are key methods in this research?
Multicenter RCTs compare RYGB/sleeve + medical therapy vs intensive medical therapy alone, tracking HbA1c, weight, and biomarkers at 1-5 years (Schauer et al., 2017; Gloy et al., 2013 meta-analysis).
What are landmark papers?
Sjöström et al. (2004; 4410 citations) SOS 10-year data shows diabetes risk reduction; Schauer et al. (2017; 2724 citations) 5-year RCT with 38% durable remission.
What open problems exist?
Relapse mechanisms beyond 5 years, optimal patient selection (duration/BMI), and weight-independent effects need clarification; limited >10-year RCTs (Sjöström, 2013).
Research Bariatric Surgery and Outcomes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Bariatric Surgery Remission of Type 2 Diabetes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Bariatric Surgery and Outcomes Research Guide